CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-31 | BENEVICH ERIC Chief Commercial Officer | Shares withheld for taxes | −1,292 | $136.06 | $176K | 52,755 |
| 2026-01-31 | BENEVICH ERIC Chief Commercial Officer | Option exercise · Restricted Stock Unit | −2,294 | 0 | ||
| 2026-01-31 | Gano Kyle Chief Executive Officer | Option exercise | +2,927 | 143,334 | ||
| 2026-01-31 | Gano Kyle Chief Executive Officer | Shares withheld for taxes | −1,580 | $136.06 | $215K | 141,754 |
| 2026-01-31 | Gano Kyle Chief Executive Officer | Option exercise · Restricted Stock Unit | −2,927 | 0 | ||
| 2026-01-31 | Lippoldt Darin Chief Legal Officer | Option exercise | +2,373 | 49,127 | ||
| 2026-01-31 | Lippoldt Darin Chief Legal Officer | Shares withheld for taxes | −1,335 | $136.06 | $182K | 47,792 |
| 2026-01-31 | Lippoldt Darin Chief Legal Officer | Option exercise · Restricted Stock Unit | −2,373 | 0 | ||
| 2026-01-31 | GORMAN KEVIN CHARLES Director | Option exercise | +5,142 | 519,738 | ||
| 2026-01-31 | GORMAN KEVIN CHARLES Director | Shares withheld for taxes | −2,845 | $136.06 | $387K | 516,893 |
| 2026-01-31 | GORMAN KEVIN CHARLES Director | Option exercise · Restricted Stock Unit | −5,142 | 0 | ||
| 2026-01-16 | Gano Kyle Chief Executive Officer | Option exercise 10b5-1 | +34,588 | $35.99 | $1.2M | 174,995 |
| 2026-01-16 | Gano Kyle Chief Executive Officer | Sale 10b5-1 | −34,588 | $132.70 | $4.6M | 140,407 |
| 2026-01-16 | Gano Kyle Chief Executive Officer | Option exercise 10b5-1 | +1,812 | $35.99 | $65K | 142,219 |
| 2026-01-16 | Gano Kyle Chief Executive Officer | Sale 10b5-1 | −1,812 | $132.71 | $240K | 140,407 |
| 2026-01-16 | Gano Kyle Chief Executive Officer | Option exercise · Non-Qualified Stock Option 10b5-1 | −34,588 | 0 | ||
| 2026-01-16 | Gano Kyle Chief Executive Officer | Option exercise · Incentive Stock Option 10b5-1 | −1,812 | 0 | ||
| 2026-01-08 | Lippoldt Darin Chief Legal Officer | Option exercise | +3,349 | $35.99 | $121K | 46,754 |
| 2026-01-08 | Lippoldt Darin Chief Legal Officer | Option exercise · Incentive Stock Option | −3,349 | 0 | ||
| 2025-12-16 | Norwalk Leslie V Director | Sale 10b5-1 | −1,190 | $155.09 | $185K | 6,239 |
Page 15 of 49 · 963 trades